The development of humanized monoclonal antibodies or other therapeutics targeting CD93 may offer new treatment options for patients with inflammatory disorders, cardiovascular diseases, and various cancers, potentially leading to improved clinical outcomes. Here, CD93 is linked to cardiovascular disorder.